Largest ever global study of tuberculosis identifies genetic causes of drug resistance

Largest ever global study of tuberculosis identifies genetic causes of drug resistance
Structural study of antibiotic opens the way for new TB treatments Credit: Shutterstock

Using cutting-edge genomic sequencing techniques, researchers at the University of Oxford have identified almost all the genomic variation that gives people resistance to 13 of the most common tuberculosis (TB) drug treatments.

The Comprehensive Resistance Prediction for Tuberculosis International Consortium (CRyPTIC) research project has collected the largest ever global dataset of clinical M. samples from across the world consisting of 15,211 samples from 27 countries on five continents.

Using two key advances: a new quantitative test for drug resistance and a new approach which identifies all the genetic changes in a sample of drug-resistant TB bacteria the researchers have generated a unique dataset which the team has used to quantify how changes in the genetic code of M. tuberculosis reduce how well different drugs kill these bacteria that cause TB. These innovations, combined with ongoing work in the field, promise to profoundly improve how patients with TB are treated in the future.

Tuberculosis kills more people each year than any other bacterium, virus, or parasite, except for SARS-CoV-2. Although it is treatable, drug resistance has emerged as a major problem over the past three decades. Testing for mutations in the M. tuberculosis genome to determine which drugs will give a patient the best chance of cure is the most realistic way of getting drug resistance testing to every patient who needs it.

Dr. Derrick Crook, Professor of Microbiology at the University of Oxford, said: "This innovative, large-scale, has enabled us to create possibly the most comprehensive map yet of the genetic changes responsible for drug resistance in tuberculosis."

In a series of nine new preprint manuscripts, each documenting a different aspect of how the CRyPTIC project has advanced the field, the researchers reveal:

  • How the new drug resistance tests should be interpreted and how a massive citizen science project helped solve this problem
  • How a new approach to detecting and describing genetic changes in the whole TB genome sequence improved the way driving drug resistance can be detected
  • How these data were used to scan the TB genome sequence for changes not previously known to cause drug resistance
  • How individual mutations, and combinations of mutations, can be related not just to blunt measures of "resistance" or "susceptibility," but also to even minor changes in the way a drug kills M. tuberculosis, thereby reducing the effectiveness of treatment with special attention being paid to two novel compounds being used to treat tuberculosis.
  • How artificial intelligence can predict drug resistance from signatures in the DNA sequence.
  • How these data contributed to the first list of drug resistance mutations in the TB genome to be endorsed for global use by the World Health Organization.

These results aim to help improve control of tuberculosis and facilitate the World Health Organisation's end TB strategy through better, faster and more targeted treatment of drug-resistant tuberculosis via genetic resistance prediction, paving the way towards universal susceptibility testing (DST).

"Our ultimate goal," Professor Crook says, "is to achieve a sufficiently accurate genetic prediction of resistance to most anti-tuberculosis drugs, so that whole genome sequencing can replace culture-based DST for TB. This will enable rapid-turnaround near-to-patient assays to revolutionize MDR-TB identification and management."

The data, which are now freely available, can be used by the wider scientific community to improve our understanding of in TB and how to best treat this important disease.


Explore further

Tailor-made therapy of multi-resistant tuberculosis

More information: Epidemiological cutoff values for a 96-well broth microdilution plate for high-throughput research antibiotic susceptibility testing of M. tuberculosis, (2021). DOI: 10.1101/2021.02.24.21252386

Philip W Fowler et al, BashTheBug: a crowd of volunteers reproducibly and accurately measure the minimum inhibitory concentrations of 13 antitubercular drugs from photographs of 96-well broth microdilution plates, (2021). DOI: 10.1101/2021.07.20.453060

M. Hunt et al, Minos: variant adjudication and joint genotyping of cohorts of bacterial genomes, (2021). DOI: 10.1101/2021.09.15.460475

Genome-wide association studies of global Mycobacterium tuberculosis resistance to thirteen antimicrobials in 10,228 genomes, (2021). DOI: 10.1101/2021.09.14.460272

Quantitative measurement of antibiotic resistance in Mycobacterium tuberculosis reveals genetic determinants of resistance and susceptibility in a target gene approach, (2021). DOI: 10.1101/2021.09.14.460353

Lindsay Sonnenkalb et al, Deciphering Bedaquiline and Clofazimine Resistance in Tuberculosis: An Evolutionary Medicine Approach, (2021). DOI: 10.1101/2021.03.19.436148

A generalisable approach to drug susceptibility prediction for M. Tuberculosis using machine learning and whole-genome sequencing, (2021). DOI: 10.1101/2021.09.14.458035

Alice Brankin et al, A data compendium of Mycobacterium tuberculosis antibiotic resistance, (2021). DOI: 10.1101/2021.09.14.460274

The 2021 WHO catalogue of M. tuberculosis complex mutations associated with drug resistance: A new global standard for molecular diagnostics. Walker et al. (2021) Lancet preprint. papers.ssrn.com/sol3/papers.cf … ?abstract_id=3923444

Journal information: The Lancet

Citation: Largest ever global study of tuberculosis identifies genetic causes of drug resistance (2021, October 19) retrieved 26 November 2021 from https://medicalxpress.com/news/2021-10-largest-global-tuberculosis-genetic-drug.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
 shares

Feedback to editors